ABSTRACT
having documented activity against bacteria, protozoa, fungi, plants, and cancer cell lines [8] [9] [10] [11] . In 32 addition to their bioactivity, the relative simplicity and commonality of PTM biosynthetic loci has 
36
The clifednamides are a family of PTMs discovered from Streptomyces sp. JV178, an 37 environmental isolate from Connecticut garden soil 16 . The clifednamides have therapeutic 38 potential due to their structural similarity with ikarugamycin, which is active against a wide range 39 of organisms 8, 10, 11 . The clifednamides are distinguished from ikarugamycin by a ketone group on 40 carbon 29 ( Figure 1A ). Despite growing research interest in PTMs, no structure-function studies 41 have been carried out thus far. Comparing the bioactivities of the long-studied ikarugamycin and 42 peer-reviewed) is the author/funder. All rights reserved. No reuse allowed without permission.
The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/197616 doi: bioRxiv preprint first posted online Oct. 3, 2017; 3 its clifednamide analogs could provide valuable insight. However, efforts to extensively profile 43 clifednamide bioactivities have been limited by low yields from JV178 (Table 1) .
44
To understand clifednamide biosynthesis towards engineering its production, JV178 was genome-45 sequenced (see Methods). Due to the structural similarity of ikarugamycin and clifednamides, we 46 expected JV178 would encode an ikarugamycin-like PTM cluster. Using BLAST, we identified a 47 5-gene PTM locus that likely encodes the clifednamides. Homology analysis of these genes 48 allowed us to propose a plausible clifednamide biosynthetic pathway ( Figure S1 ). Figure S2 ). Four such strains were obtained from the USDA NRRL strain collection. Each strain 67 was grown on a panel of solid media and extracted with ethyl acetate for LC-MS/MS analysis.
68
Clifednamide production was determined by comparison with extracts containing clifednamides
69
A and B from JV178. All four strains appear to produce both compounds based on product 70 retention times, UV absorbance spectra, and mass fragmentation patterns (Figure 2) . Notably, S.
71
negayawaensis produced approximately 26 μM of clifednamides A and B combined, about 10-
72
fold greater than JV178 ( Figure 2E , other Streptomyces metabolites, this lesion also increased PTM production 23 ( Figure 3A&B ).
80
Markerless cftA deletion resulted in the loss of clifednamide production. However, the strain 81 produced increased amounts of a previously minor compound (m/z 479) ( Figure 3C ). This peak Table   104 1). No clifednamide B or butremycin was observed in any of these strains due to ftdA being absent 105 in the host. In general, constructs driven by the stronger pHM11a 28 -derived promoter converted 106 more ikarugamycin precursor to clifednamide A than the pDA1652-derived promoter 29 .
107
Additionally, all four pHM11a constructs and two pDA1652 constructs resulted in a new peak The 
116
The subsequent oxidation of clifednamide A to clifednamide C is consistent with a hydroxylation
117
(m/z +16), perhaps resulting from above-optimal CftA activity. A clifednamide C peak was also 118 detected in S. negayawaensis, confirming its production in un-engineered clifednamide producers.
119
The tandem oxidation of clifednamide A by CftA is analogous to the activity of the recently 
162
Standard protocols for manipulating E. coli were based on those of Sambrook et al 33 .
163
Streptomycetes were routinely propagated on ISP2 agar 34 and Trypticase Soy Broth (Difco) at 164 28˚C. Glass beads were added to liquid cultures to disrupt mycelial clumps.
165
Genome sequencing of JV178 Genomic DNA was extracted from TSB-grown mycelia as de novo assembled using the CLC Genomics Workbench (CLC Bio-Qiagen, Aarhus, Denmark).
171
An annotated sequence for the Streptomyces sp. JV178 clifednamide cluster was deposited to
172
GenBank (accession no. MF89327). 
Streptomycete conjugations. S. sp. F-6131 spores were collected from ISP4 agar 34 , while S. sp.
174
F-2890 spores were collected from ISP2 agar. Spores were harvested using TX Buffer 36 .
175
Conjugations were performed using JV156 as the general E. coli donor as previously described 7 .
176
Exconjugants were selected with 50 µg/mL colistin and 25 or 50 µg/mL apramycin. Successful was amplified using primers YQ273 and YQ274 (introduced a XbaI site and homology to pUC19).
185
The 1079 bp downstream flanking region of cftA was amplified using primers YQ275 (introduced JV739 by intergeneric conjugation, and apramycin-resistant (Apr R ) exconjugants were selected.
192
Exconjugants were grown in TSB non-selectively at 37˚C and double-recombinants were selected Qualitative Analysis software. PTMs were quantified using integrated peak areas of absorbance at 217 320nm detected with an in-line diode array detector (DAD). A standard curve was generated using 218 an authentic ikarugamycin standard. 
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